Methods of using antibodies against human IL-22

Details Methods of using antibodies against human IL-22 Methods of using antibodies against human IL-22

2009-05-29

2010-12-07

Bunner, Bridget E (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S141100, C424S130100, C424S133100, C530S351000, C530S389100, C514S012200

Reexamination Certificate

active

07846444

ABSTRACT:
The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.

REFERENCES:
patent: 5350836 (1994-09-01), Kipchick et al.
patent: 5536637 (1996-07-01), Jacobs
patent: 5674487 (1997-10-01), Smith et al.
patent: 5837232 (1998-11-01), De Waal Malefyt et al.
patent: 5863796 (1999-01-01), Moore et al.
patent: 6143867 (2000-11-01), Akerblom
patent: 6225117 (2001-05-01), Gately et al.
patent: 6274710 (2001-08-01), Dumoutier et al.
patent: 6331613 (2001-12-01), Dumoutier et al.
patent: 6359117 (2002-03-01), Dumoutier et al.
patent: 6551799 (2003-04-01), Gurney et al.
patent: 6939545 (2005-09-01), Jacobs et al.
patent: 7279559 (2007-10-01), Jacobs et al.
patent: 7307161 (2007-12-01), Jacobs et al.
patent: 7459533 (2008-12-01), Jacobs et al.
patent: 2001/0006637 (2001-07-01), Akahoshi et al.
patent: 2001/0023070 (2001-09-01), Ebner et al.
patent: 2001/0024652 (2001-09-01), Dumoutier et al.
patent: 2002/0012669 (2002-01-01), Presnell et al.
patent: 2002/0102723 (2002-08-01), Gurney et al.
patent: 2002/0177165 (2002-11-01), Ashkenazi et al.
patent: 2002/0187523 (2002-12-01), Tang et al.
patent: 2003/0003545 (2003-01-01), Ebner et al.
patent: 2003/0012788 (2003-01-01), Renauld et al.
patent: 2003/0092133 (2003-05-01), Ebner et al.
patent: 2003/0170823 (2003-09-01), Presnell et al.
patent: 2004/0023341 (2004-02-01), Xu et al.
patent: 2004/0110189 (2004-06-01), Dumoutier et al.
patent: 2004/0152125 (2004-08-01), Presnell et al.
patent: 2004/0180399 (2004-09-01), Renauld et al.
patent: 2005/0042220 (2005-02-01), Li et al.
patent: WO 94/01548 (1994-01-01), None
patent: WO 99/61617 (1999-12-01), None
patent: WO 00/24758 (2000-05-01), None
patent: WO 00/70049 (2000-11-01), None
patent: WO 00/73457 (2000-12-01), None
patent: WO 00/77037 (2000-12-01), None
patent: WO 01/46422 (2001-06-01), None
patent: WO 02/10393 (2002-02-01), None
patent: WO 02/16611 (2002-02-01), None
patent: WO 02/068476 (2002-09-01), None
patent: WO 2005/000897 (2005-01-01), None
Sugimoto et al. Gastroenterology: 2006: 130; 4: Suppl. 2: A41.
Sugimoto et al. Gastroenterology: 2005: 128: Suppl. 2: A18.
Van Deventer et al. Reaserach and Clinical Forums. 1998; 20; 11-18.
Andoh et al., “Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts”, Gastroenterology: 2005 129:969-84.
Brand et al. Am. J. Physiol. Gastrointest. Liver Physiol.: 2006: 290:G827-38.
Sugimoto et al., “IL-22 Ameliorates intestinal inmflammation in a mouse model of ulcerative colitis”, The Journal of Clinical Investigation: 2008: 118:534-44.
Mahairas G. et al., Database Est. Accession No. AQ104025. Aug. 1998.
Waterston R. et al., Database GenEmbl. Accession No. AC006734. Feb. 25, 1999.
Wilson R. et. al. J. Mol. Biol. 261:155-172,1996.
Bork et al., Trends in Genetics 12:425-427, 1996.
Vukicevic et al., PNAS USA 93:9021-26, 1996.
Massague, J. Cell 49:437-8, 1987.
Pilbeam et al., Bone 14:717-720, 1993.
Skolnick et al., Trends in Biotech. 18:34-39, 2000.
Syrbe et al., (1999) Springer Seminars in Immunopathology, 21:263-85.
Dumoutier, L. et al., GenBank Accession No. NM—016971 for Mus musculus interleukin 10-related T cell-derived inducible factor (Iltif). Jun. 8, 2000.
Aoki, I., et al Comparison of the amino acid and nucleotide sequences between human and two guinea pig major basic proteins,: FEBS Lett. 282(1):56-60, 1991.
Dumoutier, L. et al., “IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes,” Genes Immun. 1:488-494, 2000.
Ozaki, T. et al. GenBank Accession No. D13973 for Dictyostelium discoideum DNA for Dp87 protein, 1993. Feb. 1, 2000.
Aoki, I., et al. GenBank Accession No. P35709 for Eosinophil granule major basic protein 2 precursor (mbp-2). May 30, 2000.
Xie, M. et al. GenBank Accession No. AF279437 forHomo sapiensinterleukin 22 (IL22). Oct. 9, 2000.
Dumoutier, L., et al., GenBank Accession No. AJ294727 for Mus musculus ILTIFa gene for IL TIE alpha protein (LI-21), exons la. Dec. 21, 2000.
Dumoutier, L., et al., GenBank Accession No. NP—065386 for Interleukin 22; Interleukin 21; IL-10-related T-cell-derived inducible factor (Homo sapiens). Nov. 2, 2000.
Ozaki, T., et al., Developmental regulation of transcription of a novel prespore-specific gene (Dp87) in Dictyostelium doscoideum,: Development. 117(4):1299-308, 1993.
Sambrook, J. et al., Molecular Cloning. A Laboratory Manual, 2d ed. Cold Spring Harbor Laboratory Press, 1989, Ch. 17.
Kotenko, Sergei V. et al., Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, MD, US, vol. 276, No. 4, Jan. 26, 2001, pp. 2727-2732.
Dumoutier, L. et al., “IL-TIF induces acute phase reactant production by heatocytes through IL-10Rbeta.” Immunology Letters, vol. 73, No. 2-3 Sep. 2000, p. 261.
Lambert, A. et al., Toxicologic Pathology, vol. 29, No. 6, Nov. 2001, p. 712.
Bork, P., Genome Research 10:398-400, 2000.
Mahairas, et al., PNAS, USA, 96(17) 739-9744 (1999).
Simon L.S., et al., (Jun. 2000), New and future drug therapies for rheumatoid arthritis, Rheumatology 39: 36-42.
Llorente L., et al. (2000) Arthritis and Rheumatism 43(8): 1790-1800.
Dumoutier, L. et al., (2000), J. of Immunol. 164:1814-1819.
Dumoutier, L. et al., PNAS 97(18): 10144-9, 2000.
Xie, M. et al., J. Biol. Chem. 275(40):31335-9, 2000.
Van Den Berg, W. (1998), Joint inflammation and carilage destruction may occur uncoupled, Springer Sem Immunopathol. 20:149-164.
R&D Systems, Catalog NR, AF582, XP002307633, “Anti-Mouse IL-22 Antibody”, Aug. 22, 2002.
Kotenko, Sergei, Cytokine and Growth Factor Reviews, vol. 13, No. 3, Jun. 2002, pp. 223-240.
Radaeva, Svetlana, et al., Hepatology, vol. 39, No. 5, May 2004, pp. 1332-1342.
Resmini, C., et al., European Cytokine Network, vol. 14, No. Sup. 3, Sep. 2003, p. 129 and Annual Meeting of Int'l Cytokine Society; Dublin, Sep. 20-24, 2003. ISSN:1448-5493.
Li, J., et al, International Immunopharmacology, Elsevier, Amsterdam, NL, vol. 4, No. 5, May 2004, pp. 693-708.
Amelizad Z et al. Accession No. A60822, Biochem. Pharmacol. 37, 3245-3249, 1988.
International Search Report from PCT/US2007/004692, Aug. 26, 2008.
International Report on Patentability and Written Opinion of the International Searching Authority for PCT/US2007/004692, Aug. 26, 2008.
International Search Report from PCT/US2007/004430, Aug. 26, 2008.
International Report on Patentability and Written Opinion of the International Searching Authority for PCT/US2007/004430, Aug. 26, 2008.
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.
Lederman et al., Molecular Immunology, 1991, vol. 28, pp. 1171-1181.
Li et al., Proc Natol Acad Sci USA, 1980, vol. 77, pp. 3211-3214.
Daniel et al., Virology, 1994, vol. 202, pp. 540-549.
Mikayama et al., Proc. Natl. Acad. Sci. USA (1993) 90:10056-60.
Rudikoff et al., Proc. Natl. Acad. Sci. USA (1982) 79:1979-83.
Boniface et al., J. Immunol. (2005) 174:3695-702.
Zheng et al., Nature (2007) 445:648-51 and S1-S15.
Ikeuchi et al., Arthritis & Rheumatism (2005) 52:1037-46.
Wirtz et al., Nature Protocols (2007) 2:541-46.
Zenewicz et al., Immunity (2008) 29:947-57.
Carvahlo et al., Inflamm Bowel Dis. (2008) 14:1051-60.
Dumoutier et al., “Absence of IL-22 aggravates dextran-sulfate [DSS] induced colitis,” Abstract #42, Cyokine, (2008) 43:243-262.
Ouyang et al., Mucosal Immunology (2008) 1:335-338.
Wolk et al., J. Immunology (2007) 178:5973-81.
Schmechel et al., Inflamm Bowel Dis. (2008) 14:204-12.
Communication Pursuant to Article 94(3) EPC dated Nov. 10, 2009 from European Patent Application No. 07 751 204.4.

Affiliated with

Also associated with

Rating

Methods of using antibodies against human IL-22 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of using antibodies against human IL-22, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using antibodies against human IL-22 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4163289